Early Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed an ethics board-approved consent form agreeing to take part in the study
- Adults aged 18 or older (men and women)
- People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by a tissue or cell sample
- People who have been newly diagnosed with pancreatic cancer that cannot be surgically removed, is locally advanced, or has spread to other parts of the body (confirm with trial site for exact definitions)
- People whose main pancreatic tumour can be treated with a focused ultrasound procedure (called HIFU) and can be seen clearly on an abdominal ultrasound scan
- People whose main tumour meets specific size and visibility requirements used to measure treatment response
- People who are generally well enough to carry out light activity and care for themselves, as rated by a standard medical scale (ECOG score of 0 or 1)
- People who are expected to live for at least 3 months
- People whose blood counts, kidney function, and liver function meet minimum levels set by the trial (confirm with trial site for specific values)
Who may not be able to join:
- People who are currently receiving active treatment for a cancer other than pancreatic ductal adenocarcinoma
- People who have already had chemotherapy or any other treatment for their pancreatic cancer
- People who have a blockage causing jaundice, unless a bile duct stent has already been placed to relieve it before the HIFU treatment begins
- People who have tumour cells blocking the veins around the pancreas
- People who have fluid-filled cysts outside the main pancreatic tumour that may be in the path of the HIFU treatment (unless the cyst is completely surrounded by the tumour)
- People whose scans show a significant narrowing of a major liver artery (more than 50%) or a complete blockage of the portal vein
- People who have an allergy to contrast dye used in scans, unless it can be managed with steroid medication beforehand
- People who have a cardiac pacemaker
- People with serious heart conditions, including heart failure, poorly controlled irregular heartbeat, or a heart attack or unstable chest pain within the past 6 months
- People whose cancer has spread to the lining of the abdomen (peritoneum)
- People with an active infection that requires treatment with medication
- People who are pregnant, breastfeeding, or who are able to become pregnant but are not willing to follow the birth control requirements described in the consent form
- People who have taken part in another clinical trial or used an unapproved treatment or device within the 30 days before the study start date
- People who the trial doctor considers unsuitable for the study for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pejman Ghanouni, MD, Stanford University
Phone: 202-615-6004
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Technical success for device feasibility
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.